NVS - Conatus May Still Have A Path Forward After Latest Phase 2b Data
Recently, Conatus Pharmaceuticals (CNAT) announced results from its phase 2b ENCORE-PH study treating patients with NASH cirrhosis portal hypertension. The primary endpoint for the overall trial wasn't met. However, I believe that the company still has a path forward for a subpopulation of compensated cirrhosis patients. This could potentially be moved forward on a subgroup analysis. For this reason, I believe that the study may still push forward. On top of that, there is another 6-month treatment extension period that will look at other clinical outcomes besides HVPG as an endpoint.